Covered recipient · General Payments record
MEDHAT FARWATI
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$24,861.86
112 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Grant | $12,500.00 | 3 |
| Travel and Lodging | $7,602.20 | 38 |
| Food and Beverage | $4,565.31 | 70 |
| Education | $194.35 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Abbott Laboratories | $16,474.55 | 37 |
| Medtronic, Inc. | $6,683.33 | 56 |
| Biosense Webster, Inc. | $1,414.71 | 16 |
| Boston Scientific Corporation | $289.27 | 3 |
Page 3 of 3; records 101–112 of 112 matching records. This page contains 12 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MEDHAT FARWATI
NPI 1104387182 · CMS profile ID 11553175
CLEVELAND, OH
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–112 of 112 matching records. This page contains 12 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1104387182?year=2025&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MEDHAT FARWATI, NPI 1104387182, CMS profile ID 11553175. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–112 of 112 matching records. This page contains 12 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104387182?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). MEDHAT FARWATI, NPI 1104387182, CMS profile ID 11553175. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–112 of 112 matching records. This page contains 12 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104387182?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- MEDHAT FARWATI, NPI 1104387182, CMS profile ID 11553175, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–112 of 112 matching records. This page contains 12 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1104387182?year=2025&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
112 matching records · $24,861.86 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–112 of 112.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Biosense Webster, Inc. | $30.73 | 03/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174111463 | CMS |
| Biosense Webster, Inc. | $44.15 | 03/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174111542 | CMS |
| Biosense Webster, Inc. | $34.44 | 03/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174111147 | CMS |
| Biosense Webster, Inc. | $16.27 | 03/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174111182 | CMS |
| Biosense Webster, Inc. | $16.27 | 03/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174111390 | CMS |
| Biosense Webster, Inc. | $96.29 | 03/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174111725 | CMS |
| Biosense Webster, Inc. | $53.61 | 03/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174111829 | CMS |
| Biosense Webster, Inc. | $341.08 | 02/06/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174111741 | CMS |
| Abbott Laboratories | $9.02 | 01/09/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1239800495 | CMS |
| Abbott Laboratories | $268.32 | 01/09/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1239802170 | CMS |
| Abbott Laboratories | $283.70 | 01/09/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1239802197 | CMS |
| Abbott Laboratories | $289.86 | 01/09/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1239802305 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $22,044.00 | 22 |
| PY2024 | Principal investigator | $21,872.40 | 20 |
| PY2023 | Principal investigator | $79.20 | 2 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
22 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Eli Lilly and Company | $33.00 | 08/25/2025 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED WITH DAPAGLIFLOZIN IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-2) | No dispute reported | 06/30/2026 | 1187872627 |
| Principal investigator 1 | Eli Lilly and Company | $165.00 | 05/20/2025 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | No dispute reported | 06/30/2026 | 1187872025 |
| Principal investigator 1 | Eli Lilly and Company | $343.20 | 04/29/2025 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187873627 |
| Principal investigator 1 | Eli Lilly and Company | $2,442.00 | 04/22/2025 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187871495 |
| Principal investigator 1 | Eli Lilly and Company | $429.00 | 04/22/2025 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) | No dispute reported | 06/30/2026 | 1187872515 |
| Principal investigator 1 | Eli Lilly and Company | $462.00 | 04/22/2025 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) | No dispute reported | 06/30/2026 | 1187873027 |
| Principal investigator 1 | Eli Lilly and Company | $79.20 | 04/22/2025 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | EXPANDED ACCESS PROGRAM FOR PIRTOBRUTINIB FOR PREVIOUSLY TREATED B-CELL CANCERS | No dispute reported | 06/30/2026 | 1187873041 |
| Principal investigator 1 | Eli Lilly and Company | $33.00 | 04/22/2025 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | STUDY OF LOXO-305 VERSUS INVESTIGATOR'S CHOICE (IDELAR OR BR) IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) (BRUIN CLL-321) | No dispute reported | 06/30/2026 | 1187873391 |
| Principal investigator 1 | Eli Lilly and Company | $99.00 | 04/22/2025 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | A MULTICENTER, PHASE 3B, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE BOWEL URGENCY AND ITS RELATIONSHIP WITH OTHER OUTCOME MEASURES IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB | No dispute reported | 06/30/2026 | 1187874625 |
| Principal investigator 1 | Eli Lilly and Company | $132.00 | 03/25/2025 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | A STUDY OF RETATRUTIDE (LY3437943) ONCE WEEKLY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND OSTEOARTHRITIS OF THE KNEE (TRIUMPH-4) | No dispute reported | 06/30/2026 | 1187872513 |
| Principal investigator 1 | Eli Lilly and Company | $1,881.00 | 03/25/2025 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | No dispute reported | 06/30/2026 | 1187873417 |
| Principal investigator 1 | Eli Lilly and Company | $396.00 | 02/18/2025 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) | No dispute reported | 06/30/2026 | 1187874311 |
| Principal investigator 1 | Eli Lilly and Company | $12,619.20 | 02/18/2025 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 1187877511 |
| Principal investigator 1 | Eli Lilly and Company | $132.00 | 02/18/2025 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | A STUDY OF RETATRUTIDE (LY3437943) ON RENAL FUNCTION IN PARTICIPANTS WITH OVERWEIGHT OR OBESITY AND CHRONIC KIDNEY DISEASE WITH OR WITHOUT TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187877529 |
| Principal investigator 1 | Eli Lilly Export S.A. Puerto Rico Branch | $66.00 | 01/21/2025 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | A STUDY OF ORFORGLIPRON (LY3502970) IN PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH INSULIN GLARGINE, WITH OR WITHOUT METFORMIN AND/?OR SGLT-2 INHIBITOR (ACHIEVE-5) | No dispute reported | 06/30/2026 | 1187874381 |
| Principal investigator 1 | Eli Lilly and Company | $237.60 | 01/21/2025 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF LOXO-305 VERSUS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED BTK INHIBITOR NAIVE MANTLE CELL LYMPHOMA (BRUIN MCL-321) | No dispute reported | 06/30/2026 | 1187871483 |
| Principal investigator 1 | Eli Lilly and Company | $165.00 | 01/21/2025 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) | No dispute reported | 06/30/2026 | 1187871837 |
| Principal investigator 1 | Eli Lilly and Company | $349.80 | 01/21/2025 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) | No dispute reported | 06/30/2026 | 1187872013 |
| Principal investigator 1 | Eli Lilly and Company | $1,353.00 | 01/21/2025 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187873089 |
| Principal investigator 1 | Eli Lilly and Company | $429.00 | 01/21/2025 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) | No dispute reported | 06/30/2026 | 1187873423 |
| Principal investigator 1 | Eli Lilly and Company | $165.00 | 01/09/2025 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | A PHASE 3, LONG-TERM SAFETY STUDY OF LY3502970 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE OR IN COMBINATION WITH ORAL ANTIHYPERGLYCEMIC MEDICATIONS (ACHIEVE-J) | No dispute reported | 06/30/2026 | 1187871475 |
| Principal investigator 1 | Eli Lilly and Company | $33.00 | 01/09/2025 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE-DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN JAPANESE ADULT PARTICIPANTS WITH OBESITY DISEASE | No dispute reported | 06/30/2026 | 1187873429 |